Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1636 1652 1677 1683
This examiner grants 100% of resolved cases
Jeffrey Lawrence Bellah is an examiner in Tech Center 1600, specifically within Art Unit 1600. The examiner has a record of 2 resolved cases, which limits the statistical breadth of the profile. The data shows an allowance rate of 100.0 percent for these matters. This 100.0 percent rate indicates that the cases resolved by this examiner so far have resulted in a grant. The 2 resolved cases provide an initial view of the examiner's work.
The interview lift is 0.0 percent, suggesting that interviews have not yet shown a statistical impact on the outcome of cases. Given the 100.0 percent allowance rate, there may have been no need for interviews to improve the chances of success in these initial matters. The median days to allowance is 1115, which provides a data point for the expected duration of prosecution. This 1115 median days to allowance represents the timeframe for reaching a grant on this docket.
The data in Art Unit 1600 shows that the interview lift is 0.0 percent, reflecting the limited data available. The 1115 median days to allowance helps set a baseline for pendency in Tech Center 1600. While the 100.0 percent allowance rate is the current record, practitioners should monitor this profile as more cases are resolved. These metrics offer an initial starting point for evaluating the examination process with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18010825 | A METHOD OF SELECTIVELY CHARACTERISING A POLYNUCLEOTIDE USING A DETECTOR | Final Rejection | Oxford Nanopore Technologies PLC |
| 18478248 | TARGETED SHRINKING OR EXPANSION OF BIOMOLECULES | Final Rejection | 10x Genomics, Inc. |
| 18362074 | METHODS AND COMPOSITIONS USING SINGLE STRAND ANNEALING PROTEINS | Non-Final OA | 10x Genomics, Inc. |
| 17685033 | METHODS AND COMPOSITIONS FOR MODIFYING PRIMARY PROBES IN SITU | Final Rejection | 10x Genomics, Inc. |
| 18478721 | REAGENT AND METHOD FOR DETECTING TARGET NUCLEIC ACID USING SAME | Non-Final OA | CANON KABUSHIKI KAISHA |
| 18291122 | SYSTEMS AND METHODS FOR CAPTURE OF CIRCULATING FREE DNA | Non-Final OA | The Johns Hopkins University |
| 18564338 | CO-MAPPING TRANSCRIPTIONAL STATES AND PROTEIN HISTOLOGY | Non-Final OA | Massachusetts Institute of Technology |
| 18277268 | SYSTEMS AND METHODS FOR DETECTING MICROORGANISM OR VIRAL LOADED AEROSOLS | Non-Final OA | Massachusetts Institute of Technology |
| 18694303 | METHODS FOR PARALLEL LAMP ASSAYS AT A SINGLE TEMPERATURE USING TEMPERATURE-SHIFTING AGENTS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY |
| 18592402 | PROBES FOR MEASURING MOLECULAR PROXIMITY IN A SAMPLE | Non-Final OA | California Institute of Technology |
| 18410620 | MOLECULAR ANALYSIS OF EXTRACELLULAR VESICLES (EVs) FOR THE PREDICTION AND MONITORING OF DRUG RESISTANCE IN CANCER | Non-Final OA | The General Hospital Corporation |
| 18547258 | HIGH-THROUGHPUT ASSESSMENT OF EXOGENOUS POLYNUCLEOTIDE- OR POLYPEPTIDE-MEDIATED TRANSCRIPTOME PERTURBATIONS | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18494008 | Method for Analyzing RNA | Non-Final OA | Shimadzu Corporation |
| 18269264 | METHOD AND KIT FOR DETECTING TARGET NUCLEIC ACID FRAGMENT | Final Rejection | Riken |
| 18322850 | SERUM EXOSOMAL SF3B4 MARKER COMPOSITION FOR DIAGNOSING EARLY STAGE HEPATOCELLULAR CARCINOMA FOR NONINVASIVE IN VITRO DIAGNOSIS | Final Rejection | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18535222 | MOLECULAR DETECTION AND COUNTING USING NANOPORES | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18414085 | CONCURRENT SEQUENCING OF FORWARD AND REVERSE COMPLEMENT STRANDS ON SEPARATE POLYNUCLEOTIDES FOR METHYLATION DETECTION | Non-Final OA | Illumina, Inc. |
| 18390578 | PALLADIUM CATALYST COMPOSITIONS AND METHODS FOR SEQUENCING BY SYNTHESIS | Non-Final OA | Illumina, Inc. |
| 18499880 | METHODS FOR DETECTING ONCOGENIC KRAS MUTATIONS | Non-Final OA | Duke University |
| 17671407 | Method for Classifying a Patient's Responsiveness to Immune Checkpoint Inhibitor Therapy | Non-Final OA | Eberhard Karls Universität Tübingen Medizinische Fakultät |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy